REG - Oxford Biomedica PLC - Director/PDMR Shareholding

Oxford BioMedicaAnnouncement

13/08/2018 11:00

RNS Number : 6138X
Oxford Biomedica PLC
13 August 2018
 


 
 
 
 
 
 
PDMR Dealings / Market Share Sale
 
Oxford, UK - 13 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 09 August 2018 James Miskin, Chief Technical Officer, exercised 11,759 options at 50p, exercised 500 options at 287.5p and 814 options at 141.5p and sold all of the resulting shares at 904.416p. 
 
Following this transaction he holds 163,272 options and no shares in the company.
 
The issued share capital of the Company is 65,752,788 ordinary shares of 50 pence each.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
 
Notification of Dealing Form
 



1.


Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")




a)


Name


James Miskin




2.


Reason for the notification




a)


Position/status


Chief Technical Officer
 




b)


Initial notification/
amendment


Initial Notification




3.


Details of the Issuer




a)


Name


Oxford BioMedica plc




b)


LEI code


213800S1GVQNXQ15K851




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument
 
Identification code


Ordinary Shares of 50 pence each
 
ISIN: GB00BDFBVT43




b)


Nature of the transaction


Exercise of options




c)


Currency


GBP - British pound




d)


Price(s) and volumes(s)


 



Price(s)


Volume(s)




£0.500


11,759




£2.875


     500




£1.415


     814



 
 




e)


Aggregated information
-   Aggregate volume
 
-   Price
 
-   Aggregated total
 


 
13,073
 
 
£0.648
 
£8,468.81




f)


Date of the transaction


2018-08-09




g)


Place of the transaction


London Stock Exchange, Main Market (XLON)



 
 



1.


Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")




a)


Name


James Miskin




2.


Reason for the notification




a)


Position/status


Chief Business Officer
 




b)


Initial notification/
amendment


Initial Notification




3.


Details of the Issuer




a)


Name


Oxford BioMedica plc




b)


LEI code


213800S1GVQNXQ15K851




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument
 
Identification code


Ordinary Shares of 50 pence each
 
ISIN: GB00BDFBVT43




b)


Nature of the transaction


Disposal




c)


Currency


GBP - British pound




d)


Price(s) and volumes(s)


 



Price(s)


Volume(s)




£9.04416


13,073



 
 




e)


Aggregated information
-   Aggregate volume
 
-   Price
 
-   Aggregated total
 


 
13,073
 
 
£9.04416
 
£118,234.30




f)


Date of the transaction


2018-08-09




g)


Place of the transaction


London Stock Exchange, Main Market (XLON)



 
-Ends-
 



For further information, please contact:


 




 
Oxford BioMedica plc:
John Dawson,  Chief Executive Officer
Stuart Paynter, Chief Financial Officer


 
Tel: +44 (0)1865 783 000




 
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton
 


 
Tel: +44 (0)20 3709 5700



 
Notes for editors
 
About Oxford BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGCGDIGUBBGIX